At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADIL Adial Pharmaceuticals
Pre-Mkt 05-28 05:06:31 EDT
2.39
+0.15
+6.70%
盘前2.41
+0.02+0.84%
04:46 EDT
High2.42Low2.18Vol87.55K
Open2.23D1 Closing2.24Amplitude10.71%
Mkt Cap5.12MTradable Cap3.13MTotal Shares2.14M
T/O197.41KT/O Rate6.68%Tradable Shares1.31M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained
TIPRANKS  ·  05-14
Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained
Adial Pharmaceuticals Q1 net loss narrows on lower R&D spending
Reuters  ·  05-11
Adial Pharmaceuticals Q1 net loss narrows on lower R&D spending
Press Release: Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Dow Jones  ·  05-11
Press Release: Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Adial Pharma’s Strategic Options: High-Stakes Search for a Deal Puts Share Price and Long-Term Prospects at Risk
TIPRANKS  ·  05-10
Adial Pharma’s Strategic Options: High-Stakes Search for a Deal Puts Share Price and Long-Term Prospects at Risk
Adial Pharmaceuticals Inc expected to post a loss of $1.21 a share - Earnings Preview
Reuters  ·  05-09
Adial Pharmaceuticals Inc expected to post a loss of $1.21 a share - Earnings Preview
Adial Pharmaceuticals Q1 EPS $(1.48) Beats $(2.73) Estimate
Benzinga  ·  05-09
Adial Pharmaceuticals Q1 EPS $(1.48) Beats $(2.73) Estimate
Adial Pharmaceuticals Q1 net loss narrows 9% to $2.02 million
Reuters  ·  05-09
Adial Pharmaceuticals Q1 net loss narrows 9% to $2.02 million
Adial Pharmaceuticals files AD04 utility application with USPTO
TIPRANKS  ·  04-30
Adial Pharmaceuticals files AD04 utility application with USPTO
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
GlobeNewswire  ·  04-29
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
Adial submits AD04 application for FDA Commissioner's National Priority Voucher pilot program
Reuters  ·  04-27
Adial submits AD04 application for FDA Commissioner's National Priority Voucher pilot program
Adial Pharmaceuticals completes AD04 demonstration batch production
TIPRANKS  ·  04-22
Adial Pharmaceuticals completes AD04 demonstration batch production
Adial completes AD04 demo batch, clearing path for planned Phase 3 trial
Reuters  ·  04-22
Adial completes AD04 demo batch, clearing path for planned Phase 3 trial
Adial Pharmaceuticals Implements New Executive Equity Compensation Plan
TIPRANKS  ·  04-10
Adial Pharmaceuticals Implements New Executive Equity Compensation Plan
Adial Pharma grants CEO Cary Claiborne 37,985 restricted stock awards
Reuters  ·  04-10
Adial Pharma grants CEO Cary Claiborne 37,985 restricted stock awards
Adial commends bipartisan H.R. 7091 to expand veterans’ access to emerging AUD therapies
Reuters  ·  03-24
Adial commends bipartisan H.R. 7091 to expand veterans’ access to emerging AUD therapies
Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate
Benzinga  ·  03-06
Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate
Press Release: Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
Dow Jones  ·  03-06
Press Release: Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  03-06
Adial Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Adial Pharma posts FY 2025 net loss of USD 8.0 million, down 40%
Reuters  ·  03-06
Adial Pharma posts FY 2025 net loss of USD 8.0 million, down 40%
Adial Pharmaceuticals enters collaboration framework agreement with Molteni
TIPRANKS  ·  03-03
Adial Pharmaceuticals enters collaboration framework agreement with Molteni

Introduction

Company Name.
Adial Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Issue price:
--